 Angion Biomedica Corp NASDAQ: ANGN has announced positive results from its Phase 1 study in healthy volunteers for ANG-3070 for fibrotic diseases. In the 97-volunteer trial, ANG-3070 achieved drug exposures in humans exceeding exposures in which activity was demonstrated in animal models of proteinuric kidney diseases. 